{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T09:40:40Z","timestamp":1793353240470,"version":"4.5.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T00:00:00Z","timestamp":1675987200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T00:00:00Z","timestamp":1675987200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s10067-023-06529-4","type":"journal-article","created":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T20:15:07Z","timestamp":1676060107000},"page":"1593-1605","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Efficacy and safety of Janus kinase inhibitors in patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"42","author":[{"given":"Fan","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaofan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huilan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0215-9176","authenticated-orcid":false,"given":"Xiaomei","family":"Leng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofeng","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,10]]},"reference":[{"issue":"2","key":"6529_CR1","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1111\/jdv.13854","volume":"31","author":"IM Michalek","year":"2017","unstructured":"Michalek IM, Loring B, John SM (2017) A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol 31(2):205\u201312. https:\/\/doi.org\/10.1111\/jdv.13854","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"19","key":"6529_CR2","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1001\/jama.2020.4006","volume":"323","author":"AW Armstrong","year":"2020","unstructured":"Armstrong AW, Read C (2020) Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA 323(19):1945\u20131960. https:\/\/doi.org\/10.1001\/jama.2020.4006","journal-title":"JAMA"},{"issue":"1","key":"6529_CR3","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.amepre.2014.02.012","volume":"47","author":"CG Helmick","year":"2014","unstructured":"Helmick CG, Lee-Han H, Hirsch SC, Baird TL, Bartlett CL (2014) Prevalence of psoriasis among adults in the U.S.: 2003\u20132006 and 2009\u20132010 National Health and Nutrition Examination Surveys. Am J Prev Med 47(1):37\u201345. https:\/\/doi.org\/10.1016\/j.amepre.2014.02.012","journal-title":"Am J Prev Med"},{"issue":"10","key":"6529_CR4","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1056\/NEJMra1505557","volume":"376","author":"CT Ritchlin","year":"2017","unstructured":"Ritchlin CT, Colbert RA, Gladman DD (2017) Psoriatic arthritis. N Engl J Med 376(10):957\u2013970. https:\/\/doi.org\/10.1056\/NEJMra1505557","journal-title":"N Engl J Med"},{"issue":"10281","key":"6529_CR5","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/s0140-6736(20)32549-6","volume":"397","author":"CEM Griffiths","year":"2021","unstructured":"Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker J (2021) Psoriasis. Lancet 397(10281):1301\u20131315. https:\/\/doi.org\/10.1016\/s0140-6736(20)32549-6","journal-title":"Lancet"},{"issue":"1","key":"6529_CR6","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41572-021-00293-y","volume":"7","author":"O FitzGerald","year":"2021","unstructured":"FitzGerald O, Ogdie A, Chandran V, Coates LC, Kavanaugh A, Tillett W et al (2021) Psoriatic arthritis. Nat Rev Dis Primers 7(1):59. https:\/\/doi.org\/10.1038\/s41572-021-00293-y","journal-title":"Nat Rev Dis Primers"},{"issue":"10136","key":"6529_CR7","doi-asserted-by":"publisher","first-page":"2285","DOI":"10.1016\/s0140-6736(18)30949-8","volume":"391","author":"F Van den Bosch","year":"2018","unstructured":"Van den Bosch F, Coates L (2018) Clinical management of psoriatic arthritis. Lancet 391(10136):2285\u201394. https:\/\/doi.org\/10.1016\/s0140-6736(18)30949-8","journal-title":"Lancet"},{"issue":"10302","key":"6529_CR8","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/s0140-6736(21)00438-4","volume":"398","author":"DP McLornan","year":"2021","unstructured":"McLornan DP, Pope JE, Gotlib J, Harrison CN (2021) Current and future status of JAK inhibitors. Lancet 398(10302):803\u2013816. https:\/\/doi.org\/10.1016\/s0140-6736(21)00438-4","journal-title":"Lancet"},{"issue":"4","key":"6529_CR9","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.immuni.2012.03.013","volume":"36","author":"GR Stark","year":"2012","unstructured":"Stark GR, Darnell JE Jr (2012) The JAK-STAT pathway at twenty. Immunity 36(4):503\u2013514. https:\/\/doi.org\/10.1016\/j.immuni.2012.03.013","journal-title":"Immunity"},{"issue":"4","key":"6529_CR10","doi-asserted-by":"publisher","first-page":"411","DOI":"10.23736\/s0392-0488.20.06658-4","volume":"155","author":"DF D'Urso","year":"2020","unstructured":"D\u2019Urso DF, Chiricozzi A, Pirro F, Calabrese L, Caldarola G, Fossati B et al (2020) New JAK inhibitors for the treatment of psoriasis and psoriatic arthritis. G Ital Dermatol Venereol 155(4):411\u201320. https:\/\/doi.org\/10.23736\/s0392-0488.20.06658-4","journal-title":"G Ital Dermatol Venereol"},{"key":"6529_CR11","doi-asserted-by":"publisher","unstructured":"L\u00e9 AM, Puig L, Torres T (2022) Deucravacitinib for the treatment of psoriatic disease. Am J Clin Dermatol 23(6):813\u2013822. https:\/\/doi.org\/10.1007\/s40257-022-00720-0","DOI":"10.1007\/s40257-022-00720-0"},{"issue":"4","key":"6529_CR12","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s40265-020-01261-8","volume":"80","author":"M Nogueira","year":"2020","unstructured":"Nogueira M, Puig L, Torres T (2020) JAK inhibitors for treatment of psoriasis: focus on selective TYK2 inhibitors. Drugs 80(4):341\u2013352. https:\/\/doi.org\/10.1007\/s40265-020-01261-8","journal-title":"Drugs"},{"key":"6529_CR13","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Bmj 372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"Bmj"},{"issue":"8","key":"6529_CR14","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1002\/art.21972","volume":"54","author":"W Taylor","year":"2006","unstructured":"Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H (2006) Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54(8):2665\u20132673. https:\/\/doi.org\/10.1002\/art.21972","journal-title":"Arthritis Rheum"},{"issue":"4","key":"6529_CR15","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1159\/000250839","volume":"157","author":"T Fredriksson","year":"1978","unstructured":"Fredriksson T, Pettersson U (1978) Severe psoriasis\u2013oral therapy with a new retinoid. Dermatologica 157(4):238\u2013244. https:\/\/doi.org\/10.1159\/000250839","journal-title":"Dermatologica"},{"issue":"6","key":"6529_CR16","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1002\/art.1780380602","volume":"38","author":"DT Felson","year":"1995","unstructured":"Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C et al (1995) American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 38(6):727\u201335. https:\/\/doi.org\/10.1002\/art.1780380602","journal-title":"Arthritis Rheum"},{"issue":"9","key":"6529_CR17","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1002\/1529-0131(199809)41:9<1564::Aid-art6>3.0.Co;2-m","volume":"41","author":"DT Felson","year":"1998","unstructured":"Felson DT, Anderson JJ, Lange ML, Wells G, LaValley MP (1998) Should improvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in core set measures, rather than twenty percent? Arthritis Rheum 41(9):1564\u20131570. https:\/\/doi.org\/10.1002\/1529-0131(199809)41:9%3c1564::Aid-art6%3e3.0.Co;2-m","journal-title":"Arthritis Rheum"},{"issue":"1","key":"6529_CR18","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1136\/ard.2008.102053","volume":"69","author":"LC Coates","year":"2010","unstructured":"Coates LC, Fransen J, Helliwell PS (2010) Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis 69(1):48\u201353. https:\/\/doi.org\/10.1136\/ard.2008.102053","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"6529_CR19","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1046\/j.1365-2133.1999.02963.x","volume":"141","author":"DM Ashcroft","year":"1999","unstructured":"Ashcroft DM, Wan Po AL, Williams HC, Griffiths CE (1999) Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their quality. Br J Dermatol 141(2):185\u2013191. https:\/\/doi.org\/10.1046\/j.1365-2133.1999.02963.x","journal-title":"Br J Dermatol"},{"key":"6529_CR20","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC, J\u00fcni P, Moher D, Oxman AD et al (2011) The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. Bmj 343:d5928. https:\/\/doi.org\/10.1136\/bmj.d5928","journal-title":"Bmj"},{"issue":"5","key":"6529_CR21","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/s0197-2456(99)00026-4","volume":"20","author":"HD Clark","year":"1999","unstructured":"Clark HD, Wells GA, Hu\u00ebt C, McAlister FA, Salmi LR, Fergusson D et al (1999) Assessing the quality of randomized trials: reliability of the Jadad scale. Control Clin Trials 20(5):448\u2013452. https:\/\/doi.org\/10.1016\/s0197-2456(99)00026-4","journal-title":"Control Clin Trials"},{"issue":"4","key":"6529_CR22","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","volume":"64","author":"H Balshem","year":"2011","unstructured":"Balshem H, Helfand M, Sch\u00fcnemann HJ, Oxman AD, Kunz R, Brozek J et al (2011) GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 64(4):401\u20136. https:\/\/doi.org\/10.1016\/j.jclinepi.2010.07.015","journal-title":"J Clin Epidemiol"},{"issue":"7414","key":"6529_CR23","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327(7414):557\u2013560. https:\/\/doi.org\/10.1136\/bmj.327.7414.557","journal-title":"BMJ"},{"issue":"3","key":"6529_CR24","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1111\/j.1365-2133.2012.11168.x","volume":"167","author":"KA Papp","year":"2012","unstructured":"Papp KA, Menter A, Strober B, Langley RG, Buonanno M, Wolk R et al (2012) Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a phase 2b randomized placebo-controlled dose-ranging study. Br J Dermatol 167(3):668\u201377. https:\/\/doi.org\/10.1111\/j.1365-2133.2012.11168.x","journal-title":"Br J Dermatol"},{"issue":"1","key":"6529_CR25","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/bjd.16004","volume":"179","author":"GJ Schmieder","year":"2018","unstructured":"Schmieder GJ, Draelos ZD, Pariser DM, Banfield C, Cox L, Hodge M et al (2018) Efficacy and safety of the Janus kinase 1 inhibitor PF-04965842 in patients with moderate-to-serve psoriasis: phase II, randomized, double-blind, placebo-controlled study. Br J Dermatol 179(1):54\u201362. https:\/\/doi.org\/10.1111\/bjd.16004","journal-title":"Br J Dermatol"},{"issue":"4","key":"6529_CR26","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1111\/bjd.14018","volume":"173","author":"KA Papp","year":"2015","unstructured":"Papp KA, Menter MA, Abe M, Elewski B, Feldman SR, Gottlieb AB et al (2015) Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials. Br J Dermatol 173(4):949\u2013961. https:\/\/doi.org\/10.1111\/bjd.14018","journal-title":"Br J Dermatol"},{"issue":"3","key":"6529_CR27","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1111\/bjd.13745","volume":"173","author":"K Papp","year":"2015","unstructured":"Papp K, Pariser D, Catlin M, Wierz G, Ball G, Akinlade B et al (2015) A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate-to-severe psoriasis. Br J Dermatol 173(3):767\u201376. https:\/\/doi.org\/10.1111\/bjd.13745","journal-title":"Br J Dermatol"},{"issue":"5","key":"6529_CR28","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1111\/bjd.14399","volume":"174","author":"VJ Ludbrook","year":"2016","unstructured":"Ludbrook VJ, Hicks KJ, Hanrott KE, Patel JS, Binks MH, Wyres MR et al (2016) Investigation of selective JAK1 inhibitor GSK2586184 for the treatment of psoriasis in a randomized placebo-controlled phase IIa study. Br J Dermatol 174(5):985\u2013995. https:\/\/doi.org\/10.1111\/bjd.14399","journal-title":"Br J Dermatol"},{"issue":"6","key":"6529_CR29","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1111\/bjd.14403","volume":"174","author":"KA Papp","year":"2016","unstructured":"Papp KA, Menter MA, Raman M, Disch D, Schlichting DE, Gaich C et al (2016) A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1\/JAK2 inhibitor, in patients with moderate-to-severe psoriasis. Br J Dermatol 174(6):1266\u201376. https:\/\/doi.org\/10.1111\/bjd.14403","journal-title":"Br J Dermatol"},{"issue":"2\u20133","key":"6529_CR30","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1159\/000475809","volume":"233","author":"T Jin","year":"2017","unstructured":"Jin T, Sun Z, Chen X, Wang Y, Li R, Ji S et al (2017) Serum human beta-defensin-2 is a possible biomarker for monitoring response to JAK inhibitor in psoriasis patients. Dermatology 233(2\u20133):164\u20139. https:\/\/doi.org\/10.1159\/000475809","journal-title":"Dermatology"},{"issue":"1","key":"6529_CR31","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jdermsci.2017.05.004","volume":"88","author":"J Zhang","year":"2017","unstructured":"Zhang J, Tsai T-F, Lee M-G, Zheng M, Wang G, Jin H et al (2017) The efficacy and safety of tofacitinib in Asian patients with moderate to severe chronic plaque psoriasis: a phase 3, randomized, double-blind, placebo-controlled study. J Dermatol Sci 88(1):36\u201345. https:\/\/doi.org\/10.1016\/j.jdermsci.2017.05.004","journal-title":"J Dermatol Sci"},{"issue":"9993","key":"6529_CR32","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/s0140-6736(14)62113-9","volume":"386","author":"H Bachelez","year":"2015","unstructured":"Bachelez H, van de Kerkhof PCM, Strohal R, Kubanov A, Valenzuela F, Lee J-H et al (2015) Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial. Lancet 386(9993):552\u2013561. https:\/\/doi.org\/10.1016\/s0140-6736(14)62113-9","journal-title":"Lancet"},{"issue":"14","key":"6529_CR33","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1056\/NEJMoa1806382","volume":"379","author":"K Papp","year":"2018","unstructured":"Papp K, Gordon K, Tha\u00e7i D, Morita A, Gooderham M, Foley P et al (2018) Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis. N Engl J Med 379(14):1313\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1806382","journal-title":"N Engl J Med"},{"issue":"16","key":"6529_CR34","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","volume":"377","author":"P Mease","year":"2017","unstructured":"Mease P, Hall S, FitzGerald O, van der Heijde D, Merola JF, Avila-Zapata F et al (2017) Tofacitinib or adalimumab versus placebo for psoriatic arthritis. N Engl J Med 377(16):1537\u201350. https:\/\/doi.org\/10.1056\/NEJMoa1615975","journal-title":"N Engl J Med"},{"issue":"16","key":"6529_CR35","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1056\/NEJMoa1615977","volume":"377","author":"D Gladman","year":"2017","unstructured":"Gladman D, Rigby W, Azevedo VF, Behrens F, Blanco R, Kaszuba A et al (2017) Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors. N Engl J Med 377(16):1525\u20131536. https:\/\/doi.org\/10.1056\/NEJMoa1615977","journal-title":"N Engl J Med"},{"issue":"10162","key":"6529_CR36","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1016\/s0140-6736(18)32483-8","volume":"392","author":"P Mease","year":"2018","unstructured":"Mease P, Coates LC, Helliwell PS, Stanislavchuk M, Rychlewska-Hanczewska A, Dudek A et al (2018) Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial. Lancet 392(10162):2367\u201377. https:\/\/doi.org\/10.1016\/s0140-6736(18)32483-8","journal-title":"Lancet"},{"issue":"13","key":"6529_CR37","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1056\/NEJMoa2022516","volume":"384","author":"IB McInnes","year":"2021","unstructured":"McInnes IB, Anderson JK, Magrey M, Merola JF, Liu Y, Kishimoto M et al (2021) Trial of upadacitinib and adalimumab for psoriatic arthritis. N Engl J Med 384(13):1227\u20131239. https:\/\/doi.org\/10.1056\/NEJMoa2022516","journal-title":"N Engl J Med"},{"issue":"3","key":"6529_CR38","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1136\/annrheumdis-2020-218870","volume":"80","author":"PJ Mease","year":"2020","unstructured":"Mease PJ, Lertratanakul A, Anderson JK, Papp K, Van den Bosch F, Tsuji S et al (2020) Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2. Ann Rheum Dis 80(3):312\u201320. https:\/\/doi.org\/10.1136\/annrheumdis-2020-218870","journal-title":"Ann Rheum Dis"},{"issue":"SUPPL 1","key":"6529_CR39","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1136\/annrheumdis-2021-eular.2603","volume":"80","author":"PJ Mease","year":"2021","unstructured":"Mease PJ, Deodhar A, Van Der Heijde D, Behrens F, Kivitz A, Kim J et al (2021) Efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with active psoriatic arthritis: results from a phase 2, randomized, doubleblind, placebo-controlled trial. Ann Rheum Dis 80(SUPPL 1):314\u2013315. https:\/\/doi.org\/10.1136\/annrheumdis-2021-eular.2603","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"6529_CR40","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/art.40726","volume":"71","author":"JA Singh","year":"2019","unstructured":"Singh JA, Guyatt G, Ogdie A, Gladman DD, Deal C, Deodhar A et al (2019) Special article: 2018 American College of Rheumatology\/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis. Arthritis Rheumatol 71(1):5\u201332. https:\/\/doi.org\/10.1002\/art.40726","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"6529_CR41","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1002\/art.39573","volume":"68","author":"LC Coates","year":"2016","unstructured":"Coates LC, Kavanaugh A, Mease PJ, Soriano ER, Laura Acosta-Felquer M, Armstrong AW et al (2016) Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol 68(5):1060\u201371. https:\/\/doi.org\/10.1002\/art.39573","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"6529_CR42","doi-asserted-by":"publisher","first-page":"102902","DOI":"10.1016\/j.autrev.2021.102902","volume":"20","author":"F Campanaro","year":"2021","unstructured":"Campanaro F, Batticciotto A, Zaffaroni A, Cappelli A, Donadini MP, Squizzato A (2021) JAK inhibitors and psoriatic arthritis: a systematic review and meta-analysis. Autoimmun Rev 20(10):102902. https:\/\/doi.org\/10.1016\/j.autrev.2021.102902","journal-title":"Autoimmun Rev"},{"issue":"8","key":"6529_CR43","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1111\/1756-185x.13616","volume":"22","author":"GG Song","year":"2019","unstructured":"Song GG, Choi SJ, Lee YH (2019) Comparison of the efficacy and safety of tofacitinib and upadacitinib in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials. Int J Rheum Dis 22(8):1563\u201371. https:\/\/doi.org\/10.1111\/1756-185x.13616","journal-title":"Int J Rheum Dis"},{"issue":"1","key":"6529_CR44","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.jaad.2017.01.053","volume":"77","author":"JF Merola","year":"2017","unstructured":"Merola JF, Elewski B, Tatulych S, Lan S, Tallman A, Kaur M (2017) Efficacy of tofacitinib for the treatment of nail psoriasis: two 52-week, randomized, controlled phase 3 studies in patients with moderate-to-severe plaque psoriasis. J Am Acad Dermatol 77(1):79-87.e1. https:\/\/doi.org\/10.1016\/j.jaad.2017.01.053","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"6529_CR45","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12895-016-0051-4","volume":"16","author":"KA Papp","year":"2016","unstructured":"Papp KA, Bissonnette R, Gooderham M, Feldman SR, Iversen L, Soung J et al (2016) Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a phase 2b randomized clinical trial. BMC Dermatol 16(1):15. https:\/\/doi.org\/10.1186\/s12895-016-0051-4","journal-title":"BMC Dermatol"},{"issue":"1","key":"6529_CR46","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/bjd.12266","volume":"169","author":"WC Ports","year":"2013","unstructured":"Ports WC, Khan S, Lan S, Lamba M, Bolduc C, Bissonnette R et al (2013) A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis. Br J Dermatol 169(1):137\u2013145. https:\/\/doi.org\/10.1111\/bjd.12266","journal-title":"Br J Dermatol"},{"issue":"4","key":"6529_CR47","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.jaad.2011.12.018","volume":"67","author":"N Punwani","year":"2012","unstructured":"Punwani N, Scherle P, Flores R, Shi J, Liang J, Yeleswaram S et al (2012) Preliminary clinical activity of a topical JAK1\/2 inhibitor in the treatment of psoriasis. J Am Acad Dermatol 67(4):658\u201364. https:\/\/doi.org\/10.1016\/j.jaad.2011.12.018","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"6529_CR48","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1093\/rheumatology\/kez087","volume":"58","author":"K Bechman","year":"2019","unstructured":"Bechman K, Subesinghe S, Norton S, Atzeni F, Galli M, Cope AP et al (2019) A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis. Rheumatology (Oxford) 58(10):1755\u20131766. https:\/\/doi.org\/10.1093\/rheumatology\/kez087","journal-title":"Rheumatology (Oxford)"},{"issue":"Suppl 3","key":"6529_CR49","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/jdv.12163","volume":"27","author":"C Horreau","year":"2013","unstructured":"Horreau C, Pouplard C, Brenaut E, Barnetche T, Misery L, Cribier B et al (2013) Cardiovascular morbidity and mortality in psoriasis and psoriatic arthritis: a systematic literature review. J Eur Acad Dermatol Venereol 27(Suppl 3):12\u201329. https:\/\/doi.org\/10.1111\/jdv.12163","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"8","key":"6529_CR50","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1136\/annrheumdis-2018-214846","volume":"78","author":"W Xie","year":"2019","unstructured":"Xie W, Huang Y, Xiao S, Sun X, Fan Y, Zhang Z (2019) Impact of Janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta-analysis of randomised controlled trials. Ann Rheum Dis 78(8):1048\u201354. https:\/\/doi.org\/10.1136\/annrheumdis-2018-214846","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"6529_CR51","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1002\/art.41580","volume":"73","author":"M Yates","year":"2021","unstructured":"Yates M, Mootoo A, Adas M, Bechman K, Rampes S, Patel V et al (2021) Venous thromboembolism risk with JAK inhibitors: a meta-analysis. Arthritis Rheumatol 73(5):779\u201388. https:\/\/doi.org\/10.1002\/art.41580","journal-title":"Arthritis Rheumatol"},{"issue":"363","key":"6529_CR52","doi-asserted-by":"publisher","first-page":"363ra149","DOI":"10.1126\/scitranslmed.aag1974","volume":"8","author":"CA Dendrou","year":"2016","unstructured":"Dendrou CA, Cortes A, Shipman L, Evans HG, Attfield KE, Jostins L et al (2016) Resolving TYK2 locus genotype-to-phenotype differences in autoimmunity. Sci Transl Med 8(363):363ra149. https:\/\/doi.org\/10.1126\/scitranslmed.aag1974","journal-title":"Sci Transl Med"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-023-06529-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-023-06529-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-023-06529-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T07:05:13Z","timestamp":1684739113000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-023-06529-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,10]]},"references-count":52,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["6529"],"URL":"https:\/\/doi.org\/10.1007\/s10067-023-06529-4","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,10]]},"assertion":[{"value":"14 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}